Fetal cell program appears to protect against acute myeloid leukemia

NewsGuard 100/100 Score

During the fetal stage, a number of so-called cell programs run that are vital to the development of the fetus. In a study published in Cell Reports, researchers from Lund University demonstrate that one of these fetal programs appears to protect against acute myeloid leukemia (AML).

We have used an experimental mouse model that always results in this type of leukemia. The interesting thing is that, when we to adult mice added a specific molecular cell program that normally only runs during fetal development, over half did not develop AML."

David Bryder, professor of experimental hematology, Lund University

The fetal program that the researchers used consists of the RNA-binding protein LIN28, the normal function of which is to regulate other genes. LIN28 is usually only expressed during fetal development and disappears shortly after birth.

"AML is the result of various cell mutations. In our research model, we can follow the development from the first mutation until the disease is established, something that is impossible to do in humans. Our mouses study shows that LIN28 has a strong prophylactic effect," says Mohamed Eldeeb, a doctoral student in Bryder's research group.

The researchers first examined samples from a large number of patients diagnosed with AML, 98 per cent of whom turned out to have no expression of LIN28 whatsoever. In those who did, the level was very low. To understand more about what happens when LIN28 is activated, the researchers then carried out more in-depth molecular and functional studies using their animal model.

"We could see that, in mice, the molecular fetal cell program protected against disease by colliding with the mechanism that drives AML, which might explain why leukemia is rare in newborns. Given the robust effect we have demonstrated, it will be interesting to study whether the fetal cell program can be used to prevent disease later in life. That said, one should be aware that it remains to be seen how we can reactive such a program in human cells," says Bryder.

Journal reference:

Eldeeb, M., et al. (2023) A fetal tumor suppressor axis abrogates MLL-fusion-driven acute myeloid leukemia. Cell Reports. doi.org/10.1016/j.celrep.2023.112099.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diet's role in fighting vitiligo highlighted in new research